Tesamorelin (Egrifta) is a research peptide and is not for human consumption. So far results have discovered it may be beneficial in people with HIV who have metabolic steatopathy (NAFLD). The study of this treatment shows it can reduce the amount of fat in the liver (steatosis) and thus prevent the development of inflammatory lesions and fibrosis. Research has also shown interesting results in favor of tesamorelin over placebo. Its early administration prevents the progression of steatosis to fibrosis in a high-risk population.